Is ImClone Out of the Woods?

Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth


Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: